The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.

NCT ID: NCT06324201

Last Updated: 2025-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-27

Study Completion Date

2028-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment, prospectively or retrospectively, to this sub-study per inclusion and exclusion criteria.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Enrolled QDOT PAS subjects are defined as consented patients with symptomatic paroxysmal atrial fibrillation (PAF) enrolled in the REAL AF registry. These enrolled subjects will be treated with the commercially available QDOT MICRO™ system (QDOT MICRO™ catheter and nGEN™ generator) in conjunction with VISITAG SURPOINT™ Module. Subjects are required to complete scheduled assessments within 12 months of the index procedure, and additional two assessments at 24 and 36-months post procedure. Retrospective consecutive patients from the REAL AF registry, who were ablated with the QDOT MICRO™ system, may be enrolled into the sub-study if the patient meets eligibility criteria and provides consent for additional follow-up of 24 and 36-months

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paroxysmal Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ablation Procedure

Ablation Procedure for paroxysmal atrial fibrillation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Symptomatic drug refractory paroxysmal (AF episode terminate spontaneously within 7 days) who, in the opinion of the investigator, are candidates for ablation for AF
2. 18 years of age or older
3. Able and willing to participate in baseline and follow up evaluations for the full length of the sub-study
4. Willing and able to provide informed consent for this sub-study

Exclusion Criteria

1. Patients who have undergone catheter ablation for atrial fibrillation (PVI, roof line, posterior wall ablation...)
2. Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
3. Persistent or long-standing persistent AF
4. In the opinion of the investigator, any known contraindication to an ablation procedure
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biosense Webster, Inc.

INDUSTRY

Sponsor Role collaborator

Heart Rhythm Clinical and Research Solutions, LLC

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brian Sanchez, MD

Role: STUDY_DIRECTOR

J & J Corporation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arrhythmia Institute at Grandview

Birmingham, Alabama, United States

Site Status RECRUITING

Mobile Cardiology Associates

Mobile, Alabama, United States

Site Status RECRUITING

Community Memorial Health System

Ventura, California, United States

Site Status RECRUITING

Medical City - HCA

Aurora, Colorado, United States

Site Status RECRUITING

Naples Community Hospital

Naples, Florida, United States

Site Status WITHDRAWN

Sarasota Memorial Health

Sarasota, Florida, United States

Site Status RECRUITING

Piedmont Healthcare

Atlanta, Georgia, United States

Site Status RECRUITING

Norton Heart and Vascular Institute

Louisville, Kentucky, United States

Site Status RECRUITING

The Brigham and Womens Hospital

Boston, Massachusetts, United States

Site Status NOT_YET_RECRUITING

Sparrow Clinical Research Institute

Lansing, Michigan, United States

Site Status RECRUITING

Trinity Health-Michigan Heart

Ypsilanti, Michigan, United States

Site Status RECRUITING

The Christ Hospital

Cincinnati, Ohio, United States

Site Status RECRUITING

University of Cincinnati

Cincinnati, Ohio, United States

Site Status RECRUITING

University of Pennsylvania (UPENN)

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Allegheny Health

Pittsburgh, Pennsylvania, United States

Site Status RECRUITING

Centra Health, Inc.dba Stroobants Cardiovascular Center

Lynchburg, Virginia, United States

Site Status RECRUITING

Bon Secours Medical Group - Richmond Specialty Care

Richmond, Virginia, United States

Site Status RECRUITING

Valley Health System

Winchester, Virginia, United States

Site Status RECRUITING

Multicare Health Systems-Pulse Heart

Puyallup, Washington, United States

Site Status RECRUITING

Franciscan Heart and Vascular Associates

Tacoma, Washington, United States

Site Status RECRUITING

Mercy Health

Janesville, Wisconsin, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jennifer Moss

Role: CONTACT

615-448-5770

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Cindy Baumann

Role: primary

Kaitlyn Phetteplace

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

QDOT PAS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Atrial Fibrillation Progression Trial
NCT01570361 TERMINATED PHASE4